My takeaways:
Investments in Q4 show strategy and positioning - future of the company is in the 50,000 retail stores clearly... they are investing significantly to handle the contracts with FDMC - they are ready for big time partners, far beyond manual fulfillment to the Natural Stores. And doing it while increasing profit. Nice management and thinking of investors.
More clarity on the likely FDA channels they seem to be hearing: 1 Pharma channel (for us longer term 007); 2 FDMC products (main PLusCBD still #1 in category re SPINS Data); and any CBD products derived from THC MJ instead of hemp may be in trouble - Dowling seems to have heard those will be pulled and banned. That was very interesting and he went into detail about our clear traceability of hemp fiber. (That should be good for CW too with their special hemp strains, but they started from MJ years ago I read today.)
Glad he said FDMC retailers know GRAS well and recognize it. (As the kids would say, GRAS recognize GRAS...) Gras for us not for all.
Q4 growth over Q3 despite tougher headwinds from some states; looks like other positive growth channels that they may be looking to share breakout in Q1 2019 - good sign for late April when we get those numbers;
Raw Materials - good amounts; traceable and verifiable for FDA;
Mona was a non-issue and not reactive, just played out the transitions after SEC settled. Disproves some conspiracy idiots we have battled.
Sort term - for two Q in a row, the guesses show this board is still too optimistic on time frames for the big moves on revenue and stock price pop. (Dowling clearly said Q4 would be choppy based on state interference in Nov on the Q3 call.) Those who want it to go down, will take advantage of the traders tomorrow and maybe the rest of this week. No near term obvious catalysts and we know what they can do to a great profitable company wallowing on the shit show known as the OTC. I will try to buy more lower, but I own a lot already and with audited financials out, I expect NASD is soon.
